ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)
June 18, 2021Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®# (tenofovir alafenamide 25 mg, TAF) from ... -
Vemlidy(r) Demonstrates Continued Efficacy and Improved Safety for Asian Patients with Hepatitis B
February 04, 2021Gilead Sciences announced today at the 2021 Asian Pacific Association for the Study of the Liver Conference (APASL), findings from two sub-analyses that demonstrated the continued efficacy and improved safety of Vemlidy® ... -
China's NMPA approves Gilead's Vemlidy for HBV
November 20, 2018HBV is highly prevalent in China with an estimated 20 million people meeting current guidelines for therapy accounting
Pharma Sources Insight January 2025
